(Refiles to correct typographical error in headline to "doses"
instead of "does")
July 31 (Reuters) - Sanofi SA and GlaxoSmithKline
Plc on Friday said they are in advanced discussions with
the European Commission to supply up to 300 million doses of the
drugmakers's experimental COVID-19 vaccine.
The doses would be manufactured in European countries
including France, Belgium, Germany and Italy.
Sanofi is leading the clinical development of the vaccine
and expects to launch a pivotal trial by the end of this year.
(Reporting By Deena Beasley; editing by Grant McCool)
Glaxosmithkline (GSK)